Почетна › Многи мијелом › Вирџинија
Kliničke studije za Многи мијелом u državi Вирџинија
20 studija za Многи мијелом traži učesnike na lokacijama u državi Вирџинија.
Gradovi u državi Вирџинија
Zvanični tekst studije (na engleskom)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT05650632A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05552222AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06106945Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06465316A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Charlottesville
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 21. 10. 2026. · NCT07735637A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07095452AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT07391657A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07073547A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06500884TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT02693535Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 8. 2026. · NCT07764978Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- и још 2
Тражи се учесникФаза 3
Сви узрасти · Оба пола · Ажурирано 10. 6. 2026. · NCT05561387Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
Тражи се учесникФаза 2
Узраст 19 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT06974786Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT05972135A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT06679101A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2025. · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 6. 2025. · NCT06119685Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.